Muscle Invasive Urothelial Carcinoma

IMvigor011: Positive Surveillance Data Demonstrate Benefits of Signatera
Surveillance data from Natera’s phase 3, randomized IMvigor011 trial, which were presented at the European Association of Urology (EAU) Congress 2024, revealed that patients with muscle invasive bladder cancer (MIBC) may benefit from Signatera, a personalized and tumor-informed molecular residual disease (MRD) test. The study was led by Thomas Powles, MBBS, MRCP, MD. ...
Advertisement

Latest News

Advertisement

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Urothelial Carcinoma
Urothelial Carcinoma

Conference Coverage

Advertisement
Advertisement
Latest News